EGCG debilitates the persistence of EBV latency by reducing the DNA binding potency of nuclear antigen 1

Biochemical and Biophysical Research Communications

Volumn 417, Issue 3, 2012, Pages 1093-1099

  Chen, Ya Lin ^a   Tsai, Hsing Lyn ^a   Peng, Chih Wen ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

Author keywords

EBNA1; EGCG; Episome maintenance; OriP; Transcriptional enhancement

Indexed keywords

ACTIN; BIOTIN; EPIGALLOCATECHIN GALLATE; EPSTEIN BARR VIRUS ANTIGEN 1; LUCIFERASE;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DNA BINDING; EPISOME; EPSTEIN BARR VIRUS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LATENT VIRUS INFECTION; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL; PROTEIN INTERACTION; UPREGULATION; VALIDATION STUDY; VIRUS LATENCY; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

CATECHIN; DNA; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; HERPESVIRUS 4, HUMAN; HUMANS; REPLICATION ORIGIN; VIRUS LATENCY; VIRUS REPLICATION;

HUMAN HERPESVIRUS 4;

EID: 84855992367     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.104     Document Type: Article

References (21)

1. Kieff E.a.R., Rickinson A.B. Epstein-Barr Virus and Its Replication. Fields Virology Fifth Ed 2007, 2603-2700. Lippincott, Williams, and WIlkins, Philadelphia. fifth ed. D. Knipe (Ed.).
2. Rawlins D.R., Milman G., Hayward S.D., et al. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 1985, 42:859-868.
3. Reisman D., Sugden B. Trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol. Cell. Biol. 1986, 6:3838-3846.
4. Yates J.L., Warren N., Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985, 313:812-815.
5. Humme S., Reisbach G., Feederle R., et al. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10989-10994.
6. Singh B.N., Shankar S., Srivastava R.K. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem. Pharmacol. 2011.
7. Fassina G., Buffa A., Benelli R., Varnier O.E., et al. Polyphenolic antioxidant (-)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. AIDS 2002, 16:939-941.
8. Nakane H., Ono K. Differential inhibitory effects of some catechin derivatives on the activities of human immunodeficiency virus reverse transcriptase and cellular deoxyribonucleic and ribonucleic acid polymerases. Biochemistry 1990, 29:2841-2845.
9. Nakayama M., Suzuki K., Toda M., et al. Inhibition of the infectivity of influenza virus by tea polyphenols. Antiviral Res. 1993, 21:289-299.
10. Imanishi N., Tuji Y., Katada Y., et al. Additional inhibitory effect of tea extract on the growth of influenza A and B viruses in MDCK cells. Microbiol. Immunol. 2002, 46:491-494.
11. Song J.M., Lee K.H., Seong B.L. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 2005, 68:66-74.
12. Choi K.C., Jung M.G., Lee Y.H., et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 2009, 69:583-592.
13. Chang L.K., Wei T.T., Chiu Y.F., et al. Inhibition of Epstein-Barr virus lytic cycle by (-)-epigallocatechin gallate. Biochem. Biophys. Res. Commun. 2003, 301:1062-1068.
14. Kang M.S., Lee E.K., Soni V., et al. Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance. J. Virol. 2011, 85:2859-2868.
15. Peng C.W., Zhao B., Chen H.C., et al. Hsp72 up-regulates Epstein-Barr virus EBNALP coactivation with EBNA2. Blood 2007, 109:5447-5454.
16. Menezes J., Leibold W., Klein G., et al. Establishment and characterization of an Epstein-Barr virus (EBC)- negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV- genome-negative African Burkitt's lymphoma. Biomedicine 1975, 22:276-284.
17. King D.J., Cooper S.J., Earle J.A., et al. A survey of serum antibodies to eight common viruses in psychiatric patients. Br. J. Psychiatry 1985, 147:137-144.
18. Hurley E.A., Klaman L.D., Agger S., et al. The prototypical Epstein-Barr virus-transformed lymphoblastoid cell line IB4 is an unusual variant containing integrated but no episomal viral DNA. J. Virol. 1991, 65:3958-3963.
19. Lycke J., Svennerholm B., Hjelmquist E., et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J. Neurol. 1996, 243:214-224.
20. Bech E., Lycke J., Gadeberg P., et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 2002, 58:31-36.
21. Chen M.R., Middeldorp J.M., Hayward S.D. Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure. J. Virol. 1993, 67:4875-4885.